Karyopharm Therapeutics Inc.

KPTI

Held by 2 specialist biotech funds

2 funds opened new positions. Next phase3 readout (Selinexor): Feb 2026. Short interest: 42.7% of float.

BiotechnologyCEO: Richard A. PaulsonIPO: 2013Website ↗

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Catalysts

Phase 2Q2 2015SelinexorDiabetic Foot UlcersNCT02367690

Primary: Presence of Local Skin Reactions (LSR) (84 days)0Sites: 1RANDOMIZED, SINGLE, TREATMENT

Phase 2NegativeQ4 2015Selinexor (KPT-330)Squamous Cell CarcinomaNCT02213133

Primary: Percentage of Participants With Disease Control Rate (DCR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (up to 14.6 months)Enrollment:45/45Sites: 18NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ1 2016SelinexorPeripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)NCT02314247

Primary: Overall Response Rate (ORR) (Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.)Enrollment:16/16Sites: 5NA, TREATMENT

Phase 2NegativeQ2 2016SelinexorProstate CancerNCT02146833

Primary: Percentage of Participants With Overall Clinical Benefit Response (CBR) (At 12 weeks)Enrollment:20/20Sites: 1RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2016selinexorRichter's TransformationNCT02138786

Primary: Percentage of Participants With Overall Response (Overall Response Rate) (Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.)Enrollment:27/27Sites: 17NA, TREATMENT

Phase 2PositiveQ1 2017SelinexorOvarian Carcinoma, Endometrial Carcinoma, Cervical CarcinomaNCT02025985

Primary: Percentage of Participants With Disease Control Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) (Baseline up to 30 days after last dose administration, assessed after 6 weeks and 12 weeks (approximately 35 months))Enrollment:116/116Sites: 4RANDOMIZED, TREATMENT

Phase 2Q2 2017SelinexorMultiple MyelomaNCT02628704

Primary: Progression Free Survival (PFS) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months)0Sites: 2RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q4 2017SelinexorMyelodysplastic SyndromeNCT02431351

Primary: Hematologic improvement (based on the 2006 International Working Group (IWG) response criteria) (6 months)0NA, TREATMENT

Phase 2PositiveQ1 2018SelinexorAcute Myeloid Leukemia (AML)NCT02088541

Primary: Overall Survival (Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks))Enrollment:317/317Sites: 78RANDOMIZED, TREATMENT

Phase 2Q1 2018SelinexorMultiple MyelomaNCT02389543

Primary: Determine maximum tolerated dose (MTD) (12 months)0RANDOMIZED, TREATMENT

Phase 2PositiveQ3 2019SelinexorMultiple MyelomaNCT02336815

Primary: Part 2: Percentage of Participants With Overall Response Rate (ORR) Per International MyelomaWorking Group (IMWG) as Assessed by an Independent Review Committee (IRC) (Baseline until disease progression/discontinuation from the study, or death, whichever occurred first (maximum duration of 17 months))Enrollment:202/202Sites: 61NON_RANDOMIZED, TREATMENT

Phase 2Q3 2020SelinexorCoronavirus InfectionNCT04355676

Primary: Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale (Baseline to Day 14)0RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2020SelinexorCoronavirus InfectionNCT04349098

Primary: Percentage of Participants With At-least a 2-Point Improvement in Ordinal Scale (Baseline up to Day 14)Enrollment:190/190Sites: 33RANDOMIZED, SINGLE, TREATMENT

Phase 3PositiveQ4 2020SelinexorDedifferentiated LiposarcomaNCT02606461

Phase 3Q1 2022SelinexorEndometrial CancerNCT03555422

Primary: Progression Free Survival (PFS) (Time from randomization until disease progression (PD) or death, whichever occurs first (approximately 12 months after the last participant enrolled))Enrollment:263/263Sites: 78RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ3 2023SelinexorGlioblastoma MultiformeNCT04421378

Phase 2NegativeQ3 2023SelinexorLocally Advanced Unresectable or Metastatic MelanomaNCT04768881

Phase 2Q3 2024Selinexor 100 mgNon-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid TumorsNCT04256707

Phase 2Q4 2025SelinexorRelapsed or Refractory Diffuse Large B-Cell LymphomaNCT04607772

Phase 3Q1 2026SelinexorMyelofibrosisNCT04562389

Phase 3Q3 2026SelinexorEndometrial CancerNCT05611931

Phase 2Q3 2026SelinexorMyelofibrosisNCT04562870

Phase 2Q4 2026SelinexorDiffuse Large B-cell LymphomaNCT02227251

Phase 3Q4 2026Selinexor (combination therapy)Relapsed/Refractory Diffuse Large B-cell LymphomaNCT04442022

Phase 2Q2 2027SelinexorMultiple MyelomaNCT02343042

Phase 2Q2 2027Selinexor 60 mgMyelofibrosis, Moderate Thrombocytopenia, Mild ThrombocytopeniaNCT05980806

Phase 2Q1 2028SelinexorMultiple Myeloma, RefractoryNCT04414475

Recent News & Research

PubMed

Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study.

# Investment Summary: KPTI Selinexor in High-Risk Multiple Myeloma This prospective observational study demonstrates selinexor (KPTI's XPO1 inhibitor) combined with standard-of-care triplet therapy (bortezomib, lenalidomide, dexamethasone) in newly diagnosed high-risk multiple myeloma patients, addressing a patient population with limited treatment options and poor prognosis. If efficacy and safety data support approval or expanded labeling, this could broaden selinexor's addressable market in the first-line setting, potentially capturing additional market share in the estimated 50,000+ annual U.S. MM diagnoses where ~15-20% carry high-risk features. The clinical validation in this high-risk subset is commercially meaningful because these patients typically have shorter overall survival and would support premium pricing and differentiated positioning versus mono-therapy

Dec 1, 2026

PubMed

Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft.

# Investment Summary: KPTI Selinexor + Sotorasib Combination This preclinical study demonstrates that selinexor (KPTI's XPO1 inhibitor) combined with sotorasib (KRAS G12C inhibitor) produces enhanced anticancer effects in KRAS G12C-mutant NSCLC models, with omeprazole preconditioning further improving efficacy. The findings suggest a potential clinical development pathway for selinexor in a large, validated oncology indication where resistance to single-agent KRAS inhibitors remains a significant clinical problem. If validated in clinical trials, this combination could expand selinexor's addressable market and differentiate the drug in a competitive KRAS-targeted landscape, though development would require partnership with sotorasib's owner (Amgen) and carries typical preclinical-to-clinic translation risk.

Aug 17, 2026

PubMed

Selinexor plus tislelizumab in patients with relapsed/refractory natural killer/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial.

# Investment Summary: KARYOPHARM THERAPEUTICS (KPTI) **Clinical Finding:** The TOUCH trial demonstrates selinexor (KPTI's XPO1 inhibitor) combined with tislelizumab produces clinical activity in heavily pretreated NK/T-cell lymphoma patients who have failed prior PD-1 checkpoint inhibitors, addressing a high unmet need in an immunotherapy-resistant population. **Commercial Implication:** This data supports potential label expansion and combination therapy positioning for selinexor beyond its current approved indications, though the narrow patient population and post-PD-1 failure setting may limit addressable market size compared to earlier-line applications. **Investor Note:** The combination approach validates selinexor's mechanism in checkpoint inhibitor-resistant disease, but investors should monitor whether this generates meaningful revenue contribution or primarily serves as supporting data for broader development strategies.

Aug 6, 2026

PubMed

Milk exosomes delivery of KPT-330 alleviates gastrointestinal adverse reactions and provides effective anti-diffuse large B-cell lymphoma therapy.

# Investment Summary: Karyopharm Therapeutics (KPTI) **Clinical/Commercial Significance:** This research demonstrates a novel milk exosome delivery platform for KPT-330 (selinexor) that reduces gastrointestinal toxicity while maintaining anti-lymphoma efficacy—a potentially meaningful advancement given that GI adverse events are a primary dose-limiting factor affecting patient tolerability and compliance with current selinexor formulations. If validated in clinical studies, this delivery approach could expand the addressable patient population by enabling higher doses or improved patient retention in DLBCL and other indications where selinexor is approved or in development. **Investor Implication:** Success would represent a valuable intellectual property opportunity and potential competitive moat around KPTI's core asset, though clinical validation and regulatory pathway clarity remain critical prerequisites to commercialization value.

Aug 1, 2026

PubMed

Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

# Investment Summary: KARYOPHARM THERAPEUTICS (KPTI) **Clinical Context:** This erratum to the Phase III SENTRY trial addresses corrections to the published data on selinexor combined with ruxolitinib in JAK inhibitor-naïve myelofibrosis patients. The correction suggests there may have been discrepancies in the originally reported efficacy or safety data that could affect the trial's interpretability and regulatory positioning. **Investor Implications:** The need for an erratum raises questions about data integrity and may complicate FDA review timelines or label claims for this combination therapy. Given KPTI's limited pipeline, any ambiguity around SENTRY results—particularly regarding superiority over ruxolitinib monotherapy—directly impacts the commercial viability of this indication and the company's ability to justify a premium pricing position in the myelofibrosis market.

Jul 30, 2026

Karyopharm Therapeutics Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research